Skip to main content

Table 2 Survival data and univariate analyses

From: Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer

  med PFS HR (95% CI) med OS HR (95% CI)
SE-Region 5.2 (3.4–7.0) 10.9 (7.8–14.0)
MPACT (Gem/Nab-arm) 5.5 (4.5–5.9) 8.5 (7.9–9.5)
Subgroup analysis
 Tumour stage
  Locally adv. 6.8 (5.2–8.4) 0.82 (0.48–1.40) p = 0.47 17.1 (7.6–26.6) 0.62 (0.32–1.18) p = 0.14
  Metastasised 4.5 (3.3–5.7) 9.4 (4.9–13.9)
 Metastatic burden
  1–3 metastases 5.5 (2.5–8.5) 0.99 (0.53–1.86) p = 0.97 10.9 (5.5–16.3) 0.63 (0.30–1.32) p = 0.22
   > 3 metastases 3.9 (2.4–5.4) 6.9 (4.8–9.0)
 ECOG
  0 6.2 (3.9–8.5) 0.93 (0.56–1.54) p = 0.77 14.5 (7.5–21.5) 0.73 (0.40–1.31) p = 0.29
  1–2 4.5 (1.1–7.9) 9.4 (6.3–12.5)
Prior chemotherapy
  Yes 6.5 (2.9–10.1) 0.82 (0.48–1.38) p = 0.45 13.2 (9.4–17.0) 0.81 (0.44–1.46) p = 0.48
  No 5.1 (3.0–7.2) 8.2 (5.3–11.1)
 Prior Surgery
  Yes 5.5 (2.1–8.9) 0.89 (0.53–1.50) p = 0.67 12.0 (9.0–15.0) 0.87 (0.48–1.58) p = 0.64
  No 5.1 (2.8–7.4) 8.9 (5.3–12.5)
  1. Survival data in months (95% CI). Upper part shows data for the entire cohort compared to the MAPCT-trial. Lower part displays univariate analyses in the respective subgroups. HR hazard ratio calculated using Cox regression analysis
\